Biotech company investigated over rabies vaccine
The State Drug Administration launched an investigation of Changchun Changsheng Bio-tech Co, which was found fudging production records for freeze-dried rabies vaccines for human use. Those suspected of violating relative laws will be transferred to public security departments.
The Administration found that the company's freeze-dried human rabies vaccine production had record violations, such as changing the vaccine production line's technological parameter.
Such activities are in complete violation of the country's drug management law and the related regulation on drug production, an official from the administration said.
The company has stopped producing its human rabies vaccine and the administration has revoked its Drug GMP Certificate (Certificate No.: JL20180024).
The administration confirmed that the company's other vaccines available in the market have been tested and do not have quality problems. To avoid any possible loophole, the administration has launched further tests on vaccine samples kept by the company.
- Yunnan border railway station sees surge in Vietnamese tourists
- Hanfu became instant hits amid Spring Festival travel rush period
- China to simultaneously issue paper and electronic death certificates from 2027
- China announces largest-ever delegation for 2026 Winter Paralympics in Italy
- Shandong unveils measures to draw young professionals
- China launches new 'healthy schools' initiative focusing on physical, mental health































